Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geodrill Announces Record First Quarter 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called... see more

Recent & Breaking News (NDAQ:GLUE)

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

GlobeNewswire March 29, 2022

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire February 3, 2022

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

GlobeNewswire January 25, 2022

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

GlobeNewswire December 2, 2021

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 22, 2021

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

GlobeNewswire November 10, 2021

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

GlobeNewswire October 20, 2021

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer

GlobeNewswire October 7, 2021

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

GlobeNewswire September 30, 2021

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

GlobeNewswire September 10, 2021

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

GlobeNewswire September 8, 2021

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

GlobeNewswire August 12, 2021

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

GlobeNewswire June 23, 2021